The week of September 28–October 4, 2026 brought notable developments across U.S. regulatory costs, next-generation implantable devices, digital electrophysiology and Japanese MedTech M&A.
FDA's FY2027 medical-device user fees took effect on October 1, while the agency also advanced its READI-Home initiative for home-use devices. Product highlights included MED-EL's fully implantable cochlear implant, new Medtronic cardiac-ablation software and Siemens Healthineers' next-generation D-dimer assay. In Japan, Terumo agreed to acquire Arsenal Medical, while MHLW issued corrections to previously published device reimbursement information.
1. FDA FY2027 Medical Device User Fees Take Effect
Effective date: October 1, 2026
FDA's FY2027 Medical Device User Fee Amendments rates apply from October 1, 2026 through September 30, 2027. The standard 510(k) fee increased from $26,067 to $28,653, the De Novo fee from $173,782 to $191,020, and the PMA and related standard fee to $636,732.
The annual establishment registration fee increased to $13,785, compared with $11,423 in FY2026. Qualified small businesses may pay reduced application fees, including $7,163 for a 510(k) and $47,755 for a De Novo request.
For overseas manufacturers planning U.S. entry, these fees should be incorporated directly into regulatory budgets, particularly where several 510(k)s or annual establishment registration will be required.
Official source
https://www.fda.gov/industry/fda-user-fee-programs/medical-device-user-fee-amendments-mdufa-fees
2. FDA Advances READI-Home Innovation Challenge for Home-Use Devices
Updated: September 29, 2026
FDA announced additional participants in its READI-Home Innovation Challenge, part of CDRH's Home as a Health Care Hub Initiative. Selected developers move into an interaction phase that can include more frequent "sprint" discussions with FDA to refine device design and testing for home use.
Publicly listed participants include Epitel's wireless home EEG system, Prapela's therapeutic infant mattress, BD's home blood self-collection kit, Current Health's AI/ML software for identifying cytokine release syndrome risk following CAR-T therapy, and Skribe Medical's wearable cardiac-function patch. FDA expects to select up to nine devices.
Selection does not represent marketing authorization. However, the initiative signals growing regulatory attention to usability, caregiver operation, remote monitoring and safety outside conventional healthcare facilities.
Official source
3. MED-EL Launches Fully Implantable TICI UNICO Cochlear Implant in Europe
Published: September 29, 2026
MED-EL announced TICI UNICO, which the company describes as the world's first commercially available cochlear implant with all system components—including the microphone—implanted beneath the skin. The device has received CE Mark approval and is being introduced in several European markets.
Unlike conventional cochlear-implant systems that require an externally worn sound processor, TICI UNICO captures sound using an implanted microphone. MED-EL says recipients can continue hearing while sleeping, exercising, participating in water activities and even while the system is charging. The system is MR Conditional at 1.5T and 3T under specified conditions.
The development is significant not simply because of miniaturization, but because fully implanted systems may materially change usability and daily-life burden. Regulatory evaluation in new markets will need to consider surgical technique, charging, long-term battery performance, MRI conditions and reimbursement.
Official source
4. Medtronic Secures FDA and CE Milestones for Affera Prism-2 Mapping Software
Published: September 30, 2026
Medtronic announced FDA clearance and CE Mark for its latest Affera Prism-2 Mapping Software, used in cardiac-ablation procedures. The company also obtained CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software.
Prism-2 creates three-dimensional maps of cardiac electrical activity and uses magnetic and impedance tracking to visualize catheter position. New capabilities include Beat Matching and Pace Tagging. The ProxBox software provides real-time impedance-based feedback to help physicians assess catheter proximity to target tissue before pulsed-field energy delivery.
Electrophysiology competition is increasingly moving beyond the catheter itself toward integrated ecosystems combining mapping, navigation, energy delivery and software.
Official source
5. Siemens Healthineers Launches Innovance D-Dimer 2.0 Assay
Published: September 29, 2026
Siemens Healthineers announced the global launch of its Innovance D-Dimer 2.0 Assay, designed to support assessment of patients with suspected venous thromboembolism. The assay is CE-marked and has received FDA 510(k) clearance.
D-dimer testing is widely used to help rule out conditions such as deep-vein thrombosis and pulmonary embolism when interpreted together with clinical assessment. Siemens positions the new version as an updated assay for time-sensitive laboratory workflows.
In mature IVD categories, competitiveness depends not only on regulatory clearance but also analyzer compatibility, turnaround time, reagent supply and laboratory workflow economics.
Official source
https://www.siemens-healthineers.com/press/releases/innovance-d-dimer-assay
6. Insera Therapeutics Announces FDA Clearance for CLEAR Aspiration System
Published: September 28, 2026
Insera Therapeutics announced FDA 510(k) clearance for the CLEAR Aspiration System, designed to remove fresh, soft emboli and thrombi from peripheral arterial and venous vessels. The system combines the CLEAR Aspiration Pump with single-use catheters, tubing and canister components.
The system's distinguishing feature is cyclical aspiration, which varies aspiration rather than relying solely on continuous fixed negative pressure. The technology adds pump control and aspiration dynamics to the traditional catheter-based thrombectomy design equation.
The launch also illustrates a recurring MedTech business model in which capital equipment is paired with procedure-specific disposable components.
Primary source
7. Terumo Agrees to Acquire Arsenal Medical and NeoCast Embolic Technology
Published: September 30, 2026
Terumo announced that its subsidiary Terumo Neuro has agreed to acquire U.S.-based Arsenal Medical. The acquisition will add NeoCast, an investigational liquid embolic technology being developed for chronic subdural hematoma, to Terumo's neurovascular portfolio.
NeoCast is designed for middle meningeal artery embolization and is intended to improve penetration into distal vessels. Terumo also highlights its solvent-free characteristics. The early EMBO-02 study met feasibility and safety endpoints, while the larger RADIANT pivotal study is ongoing.
NeoCast is not currently approved in any country or region. The transaction is a notable example of a major Japanese manufacturer acquiring an overseas premarket technology and integrating clinical development, regulatory strategy and future commercialization into its portfolio.
Official source
https://www.terumo.co.jp/newsrelease/detail/20260930/11561
8. Japan MHLW Corrects Previously Issued Medical-Device Reimbursement Listings
Published: September 30, 2026
Japan's Ministry of Health, Labour and Welfare issued corrections to medical-device reimbursement notices originally dated July 31 and August 31. The notice does not establish a new reimbursement category or price; rather, it corrects previously published product information.
Corrections include product codes for Cook Medical Japan's COOK Zenith aortic dissection endovascular system and a product-name correction for Dentsply Sirona's i900 oral scanner, changing "i900 Mobile" to "i900 Mobility."
For Japan market-access teams, the notice is a reminder that reimbursement implementation requires management of product-level codes and master data even after a coverage decision has been issued.
Official source
https://www.mhlw.go.jp/content/12404000/001754572.pdf
9. Sofinnova Closes €82 Million MedTech Company-Creation Fund
Published: September 28, 2026
Sofinnova Partners announced the final close of Sofinnova MD Start IV at €82 million. The oversubscribed fund plans to create six to eight new MedTech companies across Europe and the U.S. over the next five years.
MD Start is structured around company creation rather than passive venture investing. Its previous €63 million fund backed six companies that subsequently raised more than €140 million in follow-on financing. Portfolio examples include LimFlow, preCARDIA and Moon Surgical.
Because early-stage medical devices require sustained funding for engineering, clinical evidence, manufacturing and regulatory development, hands-on venture-building models remain important to the MedTech ecosystem.
Official source
Summary
This week highlighted how the MedTech lifecycle extends well beyond regulatory clearance. FDA fees, early regulatory engagement, reimbursement master data, acquisitions and venture funding all directly influence whether technology ultimately reaches the market.
At the same time, fully implantable hearing systems, integrated cardiac-ablation software and digitally controlled thrombectomy systems demonstrate how device innovation is increasingly combining hardware, software and workflow design.
Japan was also prominent, with Terumo acquiring an investigational U.S. technology and MHLW issuing reimbursement corrections—two very different examples of the work required to move technologies from development to commercial use.